Clinical Trial Update: A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism [Phase 3]

View source ↗

Summary

Phase 3 study evaluating recombinant human luteinizing hormone (Luveris) for treating hypogonadotropic hypogonadism in Chinese women; the trial is completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadotropic Hypogonadism

Drugs mentioned

• Luveris (lutropin alfa)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Hypogonadism | Phase 3 | Status: COMPLETED | Results posted: 2012-05-22